On August 3, Krystal Biotech Inc. fell 5.31% in regular trading, trading at $322.62/share, with turnover of $26.73 million.

The decline was triggered by the company's Q2 earnings report released pre-market. While EPS of $1.79 beat the FactSet estimate of $1.62, flagship product VYJUVEK posted global net sales of $119.2 million, missing the consensus estimate of $122 million. Year-over-year revenue growth of 24% also fell short of the anticipated 32.72%. Notably, Q1 revenue had already reached $116.4 million, leaving Q2 sequential growth minimal and raising concerns about the pace of commercial ramp.

Adding to selling pressure, the stock had recently rallied following its inclusion in the S&P MidCap 400 index in late July, replacing Taylor Morrison Home. The combination of a revenue miss against an already elevated valuation prompted profit-taking. Net income for the quarter rose 43% year-over-year to $54.8 million, and VYJUVEK has now been approved in the US, Europe, Japan, and the UK.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)